Candel Therapeutics’ CAN-2409 Shows Promise in Phase 2 Trial for Pancreatic Cancer
Candel Therapeutics Inc, a clinical-stage biotechnology company focusing on developing novel immunotherapies for the treatment of cancer, recently announced positive results from its Phase 2 clinical trial of CAN-2409. This investigational immunotherapy is designed for the treatment of pancreatic ductal adenocarcinoma (PDAC), a notoriously difficult-to-treat form of pancreatic cancer.
Significant Survival Benefit for Patients with Borderline Resectable Disease
The trial, which involved 224 patients with borderline resectable PDAC, showed a significant survival benefit for those receiving CAN-2409 in combination with valacyclovir and standard-of-care chemoradiation. The estimated median overall survival for patients in the treatment group was 31.4 months, compared to just 12.5 months in the control group.
Detailed Findings of the Phase 2 Clinical Trial
The primary endpoint of the trial was met, with a statistically significant improvement in overall survival (OS) for patients receiving CAN-2409. The hazard ratio for OS was 0.49 (95% CI: 0.33-0.73; p = 0.0008). Additionally, the progression-free survival (PFS) was also significantly improved, with a hazard ratio of 0.42 (95% CI: 0.28-0.64; p < 0.0001).
Impact on Individual Patients and the Wider Community
For individuals diagnosed with PDAC, especially those with borderline resectable disease, the news of this trial comes as a ray of hope. The current standard of care for PDAC includes surgery, chemotherapy, and radiation therapy, but the disease often recurs, leading to poor prognosis. The results of this trial suggest that CAN-2409 in combination with standard-of-care treatments could offer a significant survival benefit.
Global Implications of the CAN-2409 Clinical Trial
Beyond the individual level, these findings could have a profound impact on the global community. PDAC is the third leading cause of cancer-related deaths, with a five-year survival rate of just 8%. If CAN-2409 proves to be effective in future trials and receives regulatory approval, it could become a new standard of care for PDAC treatment, potentially saving countless lives.
Conclusion
The positive results from Candel Therapeutics’ Phase 2 clinical trial of CAN-2409 offer a glimmer of hope for individuals with PDAC, especially those with borderline resectable disease. The survival benefits seen in the trial could translate into a significant improvement in clinical outcomes for patients, and potentially, a new standard of care for the treatment of PDAC. However, further research is needed to confirm these findings and determine the long-term safety and efficacy of CAN-2409. Stay tuned for updates on this promising development in cancer research.
- Candel Therapeutics Inc announces positive final overall survival data from Phase 2 clinical trial of CAN-2409 for pancreatic ductal adenocarcinoma.
- Significant survival benefit for patients with borderline resectable disease, with an estimated median overall survival of 31.4 months in the treatment group compared to 12.5 months in the control group.
- Primary and secondary endpoints of the trial were met, with statistically significant improvements in overall survival and progression-free survival.
- Individual patients with PDAC and the wider community could benefit from this development, as PDAC is a notoriously difficult-to-treat form of cancer with poor prognosis.
- Further research is needed to confirm these findings and determine long-term safety and efficacy of CAN-2409.
